Role of the Unfolded Protein Response in Beta Cell
Role of the Unfolded Protein Response in Beta Cell
批准号:
8730113
负责人:
RANDAL J. KAUFMAN
金额:
$54.4万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-01-01 至 2017-08-31
关键词:
AntioxidantsApoptosisAttenuatedBeta CellBiologicalBiological AssayBlood GlucoseCCAAT-Enhancer-Binding ProteinsCarbamazepineCaspaseCell LineCell physiologyCellsChemicalsChronicCyclosporineDataDevelopmentDiabetes MellitusDietEndoplasmic ReticulumEnsureEnvironmentExtravasationFailureGene ExpressionGenesGeneticGlucoseGrantHomeostasisHomologous ProteinHumanImageInositolInsulinInsulin ResistanceIntegral Membrane ProteinInterventionIslet CellJNK-activating protein kinaseLeadMammalian CellMediatingMembraneMembrane PotentialsMessenger RNAMethodsMitochondriaMolecularMolecular ChaperonesMusMutationN-terminalNon-Insulin-Dependent Diabetes MellitusObesityOpen Reading FramesOxidative StressPancreasPathway interactionsPatternPharmacologic SubstancePhosphorylationPhosphotransferasesProductionProinsulinProtein BiosynthesisProteinsRNA SplicingReactive Oxygen SpeciesRibosomal ProteinsRibosomesRoleSignal Recognition ParticleSignal TransductionSignal Transduction PathwaySirolimusSorting - Cell MovementStimulusStressSumTestingTissuesTransactivationTranslationsactivating transcription factorattenuationbasecell dedifferentiationcyclophilin Ddiabeticendoplasmic reticulum stressfeedingglucagon-like peptide 1human diseaseimprovedimproved functioningin vivo Modelinsightinsulin secretionisletmeetingsmitochondrial membranemouse modelnoveloverexpressionpressurepreventprotein degradationprotein foldingprotein misfoldingresponsesensortraffickingtranscription factortranslation factoruptake
中文摘要
Type 2 diabetes is associated with insulin resistance and disturbances in pancreatic p cell function that result
in inadequate glucose-stimulated insulin secretion (GSIS). However, the mechanisms that cause p cell failure
are largely unknown. Recent studies implicate protein misfolding in the ER as a potential cause for p cell
failure in diabetic humans. Upon accumulation of unfolded proteins in the lumen of the ER, PERK, IREIa,
and ATF6a are activated to increase the capacity of the ER to meet the demand for increased protein folding
and to increase the protein degradative machinery to eliminate misfolded proteins. In addition, protein
synthesis is transiently attenuated through PERK-mediated phosphorylation of elF2a. Over the past cycle we
demonstrated: 1) elF2a phosphorylation is required to limit protein synthesis and oxidative stress to maintain
P cell function; 2) the ER co-chaperone pSS""*^ is required to limit reactive oxygen species (ROS) and
preserve p cell function. Antioxidant treatment significantly restores p cell function in pSS'^*^''' mice; and 3)
IRE1a-mediated splicing of Xbp1 mRNA induces co-transiational translocation at the ER to promote
proinsulin production and represses oxidative stress. The sum of our data lead us to propose that tight
control of protein synthesis in the p cell is required to ensure the ER protein folding demand does not exceed
the capacity. This is especially important for the p cell as it is exposed to periodic postprandial increases in
protein synthesis. In our Specific Aims, we will test three hypotheses by answering the following questions:
Aim 1: Translational attenuation through elF2a phosphorylation preserves p cell function by limiting protein
misfolding. We propose that excessive proinsulin synthesis causes proinsulin misfolding, ER Ca^* release
and uptake into mitochondria, and mitochondrial-generated ROS. ROS then feed forward to further disrupt
protein folding in the ER. Any stimuli that pressure p cells to exceed their capacity for proinsulin folding will
succumb to this vicious cycle. To test this notion, we will answer:
a. Does excessive,.(Proinsulin synthesis (such as elF2aAA) cause p cell dedifferentiation and can;
antioxidants protect p cells under these conditions? We will sort GFP+ elF2aAA p cells from mice (+/- BHAsupplemented
diet) and characterize their gene expression and D N A replication/damage patterns.
b. Can reduced protein synthesis protect p cells in elF2ccAA mice? We will test whether decreased protein
synthesis through haploinsufficiency in the ribosomal protein RPL24 gene can protect elF2aAA p cells.
c. How does elF2a phosphorylation change 5' open reading frame (ORF) usage in mRNAs? Ribosomal
protection assays will be performed to elucidate how elF2a phosphorylation alters ORF usage in response
to glucose stimulation in wildtype and elF2aAA p cells.
d. Can pharmaceutical interventions protect elF2aAA p cells that produce excessive proinsulin? We will test
chemical chaperones, GLP-1, cyclosporin A, rapamycin/carbamazepine, etc. as a proof-of-concept that
elF2aAA p cell failure is due to protein misfolding and that agents known to improve ER protein folding will
improve function of p cells pressured by proinsulin synthesis.
Aim 2: Proinsulin misfolding in the ER causes Ca^* leak to mitochondria, leading to oxidative stress.
a. Does pSS""*^ deficiency cause proinsulin misfolding in the ER to disrupt mitochondrial function and
generate oxidative stress? Proinsulin synthesis, folding and trafficking, Ca^* imaging, mitochondrial
membrane potential and ROS production in islets as well as in murine immortalized p cell lines from p58"^'^*^*
and p58"''^'^' mice +/- glucose stimulation will be analyzed.
b. Can SERCA overexpression improve insulin secretion and p cell function in p58"''^"^" cells and islets?
c. Can cyclophilin D knockdown or deletion (Ppif^') prevent p cell failure in p58"''^''' cells or mice,
respectively?
d. Can interventions in Id above improve function of pSS"''^'''"islets?
For 2b-d, analyses will include methods described in 2a.
Aim 3: IREIa and ATF6a provide overlapping functions to promote SRP-dependent ribosome and mRNA
recruitment to the ER membrane during glucose stimulation and increase ER protein-folding capacity.
a. How does Irel a change membrane association of mRNAs?
b. Can antioxidants, cyclosporine A, or chemical chaperones improve ire1d'' p cell function and change
mRNA cellular localization?
c. Is Atfda and/or Atfdp deletion detrimental to p cells upon I r e l d ' ' deletion, HFD feeding, or Akita mutation?
英文摘要
Type 2 diabetes is associated with insulin resistance and disturbances in pancreatic p cell function that result
in inadequate glucose-stimulated insulin secretion (GSIS). However, the mechanisms that cause p cell failure
are largely unknown. Recent studies implicate protein misfolding in the ER as a potential cause for p cell
failure in diabetic humans. Upon accumulation of unfolded proteins in the lumen of the ER, PERK, IREIa,
and ATF6a are activated to increase the capacity of the ER to meet the demand for increased protein folding
and to increase the protein degradative machinery to eliminate misfolded proteins. In addition, protein
synthesis is transiently attenuated through PERK-mediated phosphorylation of elF2a. Over the past cycle we
demonstrated: 1) elF2a phosphorylation is required to limit protein synthesis and oxidative stress to maintain
P cell function; 2) the ER co-chaperone pSS""*^ is required to limit reactive oxygen species (ROS) and
preserve p cell function. Antioxidant treatment significantly restores p cell function in pSS'^*^''' mice; and 3)
IRE1a-mediated splicing of Xbp1 mRNA induces co-transiational translocation at the ER to promote
proinsulin production and represses oxidative stress. The sum of our data lead us to propose that tight
control of protein synthesis in the p cell is required to ensure the ER protein folding demand does not exceed
the capacity. This is especially important for the p cell as it is exposed to periodic postprandial increases in
protein synthesis. In our Specific Aims, we will test three hypotheses by answering the following questions:
Aim 1: Translational attenuation through elF2a phosphorylation preserves p cell function by limiting protein
misfolding. We propose that excessive proinsulin synthesis causes proinsulin misfolding, ER Ca^* release
and uptake into mitochondria, and mitochondrial-generated ROS. ROS then feed forward to further disrupt
protein folding in the ER. Any stimuli that pressure p cells to exceed their capacity for proinsulin folding will
succumb to this vicious cycle. To test this notion, we will answer:
a. Does excessive,.(Proinsulin synthesis (such as elF2aAA) cause p cell dedifferentiation and can;
antioxidants protect p cells under these conditions? We will sort GFP+ elF2aAA p cells from mice (+/- BHAsupplemented
diet) and characterize their gene expression and D N A replication/damage patterns.
b. Can reduced protein synthesis protect p cells in elF2ccAA mice? We will test whether decreased protein
synthesis through haploinsufficiency in the ribosomal protein RPL24 gene can protect elF2aAA p cells.
c. How does elF2a phosphorylation change 5' open reading frame (ORF) usage in mRNAs? Ribosomal
protection assays will be performed to elucidate how elF2a phosphorylation alters ORF usage in response
to glucose stimulation in wildtype and elF2aAA p cells.
d. Can pharmaceutical interventions protect elF2aAA p cells that produce excessive proinsulin? We will test
chemical chaperones, GLP-1, cyclosporin A, rapamycin/carbamazepine, etc. as a proof-of-concept that
elF2aAA p cell failure is due to protein misfolding and that agents known to improve ER protein folding will
improve function of p cells pressured by proinsulin synthesis.
Aim 2: Proinsulin misfolding in the ER causes Ca^* leak to mitochondria, leading to oxidative stress.
a. Does pSS""*^ deficiency cause proinsulin misfolding in the ER to disrupt mitochondrial function and
generate oxidative stress? Proinsulin synthesis, folding and trafficking, Ca^* imaging, mitochondrial
membrane potential and ROS production in islets as well as in murine immortalized p cell lines from p58"^'^*^*
and p58"''^'^' mice +/- glucose stimulation will be analyzed.
b. Can SERCA overexpression improve insulin secretion and p cell function in p58"''^"^" cells and islets?
c. Can cyclophilin D knockdown or deletion (Ppif^') prevent p cell failure in p58"''^''' cells or mice,
respectively?
d. Can interventions in Id above improve function of pSS"''^'''"islets?
For 2b-d, analyses will include methods described in 2a.
Aim 3: IREIa and ATF6a provide overlapping functions to promote SRP-dependent ribosome and mRNA
recruitment to the ER membrane during glucose stimulation and increase ER protein-folding capacity.
a. How does Irel a change membrane association of mRNAs?
b. Can antioxidants, cyclosporine A, or chemical chaperones improve ire1d'' p cell function and change
mRNA cellular localization?
c. Is Atfda and/or Atfdp deletion detrimental to p cells upon I r e l d ' ' deletion, HFD feeding, or Akita mutation?
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Acquisition of Zeiss LSM980 with Airyscan 2, a super-resolution point scanning confocal microscope
-
批准号:10632893
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2023
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Overcoming FVIII protein misfolding and cell toxicity
-
批准号:10560541
-
项目类别:
-
资助金额:$57.7万
-
财政年份:2022
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Overcoming FVIII protein misfolding and cell toxicity
-
批准号:10333189
-
项目类别:
-
资助金额:$58.59万
-
财政年份:2022
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Mechanism of ER protein misfolding-induced mitochondrial dysfunction
-
批准号:9448713
-
项目类别:
-
资助金额:$61.44万
-
财政年份:2017
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Mechanism of ER Protein Misfolding-Induced Mitochondrial Dysfunction
-
批准号:9750668
-
项目类别:
-
资助金额:$61.44万
-
财政年份:2017
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
-
批准号:9914228
-
项目类别:
-
资助金额:$64.77万
-
财政年份:2016
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
-
批准号:9113989
-
项目类别:
-
资助金额:$76.51万
-
财政年份:2016
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
-
批准号:9267948
-
项目类别:
-
资助金额:$70.73万
-
财政年份:2016
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Homeostatic role of IRE1a-XBP1-PDI1 in hepatic lipid metabolism
-
批准号:8888815
-
项目类别:
-
资助金额:$58.5万
-
财政年份:2015
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
eIF2a phosphorylation as a novel druggable target in CRPC
-
批准号:8805370
-
项目类别:
-
资助金额:$25.45万
-
财政年份:2015
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Homeostatic role of IRE1a-XBP1-PDI1 in hepatic lipid metabolism
-
批准号:9247167
-
项目类别:
-
资助金额:$58.5万
-
财政年份:2015
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Alteration in protein interactions with proinsulin and insulin in type 2 diabetes
-
批准号:8196049
-
项目类别:
-
资助金额:$51.76万
-
财政年份:2011
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Regulation of ER stress-induced cell death
-
批准号:7866220
-
项目类别:
-
资助金额:$61.94万
-
财政年份:2010
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Regulation of ER stress-induced cell death
-
批准号:8668936
-
项目类别:
-
资助金额:$66.38万
-
财政年份:2010
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Regulation of ER stress-induced cell death
-
批准号:8478089
-
项目类别:
-
资助金额:$56.3万
-
财政年份:2010
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Regulation of ER stress-induced cell death
-
批准号:8300171
-
项目类别:
-
资助金额:$58.35万
-
财政年份:2010
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Regulation of ER stress-induced cell death
-
批准号:8733250
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2010
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Regulation of ER stress-induced cell death
-
批准号:8300329
-
项目类别:
-
资助金额:$55.6万
-
财政年份:2010
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
Role of the Unfolded Protein Response in Beta Cell
-
批准号:7996351
-
项目类别:
-
资助金额:$27.11万
-
财政年份:2009
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
HTP chemical genomic screens to identify positive regulators of the Unfolded Prot
-
批准号:7845328
-
项目类别:
-
资助金额:$3.86万
-
财政年份:2009
-
负责人:RANDAL J. KAUFMAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: